Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
102.00    2.10 (2.10%)
Bid:
101.00
Ask:
102.00
Spread: 1.00 (0.99%)
Market Cap: £620.36m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Dividend Declaration

5 Jul 2016 18:33

BACIT LIMITED - Dividend Declaration

BACIT LIMITED - Dividend Declaration

PR Newswire

London, July 5

BACIT Limited (the "Company")

(a closed-ended collective investment scheme established as a company with limited liability under the laws of Guernsey with registered number 55514)

2016 Dividend5 July 2016

The Board of the Company is pleased to announce a dividend equivalent to 2.20 pence per ordinary share for the year ended 31 March 2016 (the “2016 Dividend”). The 2016 Dividend will be paid on 19 August 2016 to holders of ordinary shares recorded on the register as at the close of business on 15 July 2016.

The Board has determined that the 2016 Dividend will be paid to the Qualifying Shareholders (as defined below) in the form of new ordinary shares unless those shareholders elect to receive the dividend in cash instead. The number of new shares that each Qualifying Shareholder will receive in payment of the 2016 Dividend will be determined by multiplying the number of existing shares held by the shareholder on the record date by the cash equivalent amount of the 2016 Dividend per share and dividing the resulting number by the net asset value per share of the Company as at 30 June 2016, and then rounding the result down to the nearest whole number. Fractions of new shares will not be issued and cash that otherwise would have been applied by the Company in paying up those fractions will be retained by the Company.

A “Qualifying Shareholder” is a shareholder who is not located in, or with a registered address in, or a citizen of any of the United States, Australia, Canada, Japan, South Africa or any other jurisdiction in respect of which the offer of new shares would or may be unlawful.

Shareholders who are not Qualifying Shareholders will receive the 2016 Dividend in cash. In addition, Qualifying Shareholders can elect to receive the 2016 Dividend in cash. A circular and form of election will be sent to shareholders during the week commencing 11 July 2016. Qualifying Shareholders who wish to receive the 2016 Dividend in cash should complete and return the form of election by 5.00pm on 3 August 2016.

Timetable:

Posting of Circular and Forms of ElectionExpected during the week commencing 11 July 2016
Shares quoted ex-dividend14 July 2016
Record date for dividend15 July 2016
Announcement of the 30 June 2016 NAVExpected during the week commencing 25 July 2016
Final date for receipt by the Receiving Agent of forms of election by Qualifying Shareholders who wish to receive cash5 p.m. on 3 August 2016
Dividend payment date19 August 2016
Shares to be issued and cash to be paid to shareholders who have opted for the cash dividend19 August 2016

In compliance with LR 9.6.1, copies of the following documents will be submitted to the National Storage Mechanism at the same time as they are issued and will be available for inspection at www.hemscott.com/nsm.do:

1.2016 Dividend Circular

2.Form of election

Enquiries:

Company website: www.bacitltd.com

Northern Trust International Fund Administration Services (Guernsey) Limited Martin Bourgaize

+44 (0) 1481 745819

meb16@ntrs.com

Page 2

Date   Source Headline
30th May 202312:44 pmRNSFreeline reports Q1 2023 Financial Results
19th May 202311:00 amRNSNotice of Results
15th May 20233:16 pmRNSHolding(s) in Company
12th May 202311:14 amRNSHolding(s) in Company
10th May 202312:20 pmRNSAchilles reports Q1 2023 Financial Results
4th May 202312:05 pmRNSAutolus reports Q1 2023 Financial Results
24th Apr 20233:09 pmRNSHolding(s) in Company
19th Apr 20234:57 pmRNSHolding(s) in Company
4th Apr 202312:05 pmRNSFreeline reports Full Year 2022 Financial Results
4th Apr 202312:05 pmRNSSyncona expands portfolio with £22.5m Series A
13th Mar 20237:00 amRNSUpdate re. Silicon Valley Bank
7th Mar 202312:05 pmRNSAchilles reports Q4 and full year 2022 Results
7th Mar 202312:05 pmRNSAutolus reports full year 2022 Financial Results
7th Feb 20237:00 amRNSThird Quarter Update
22nd Dec 20227:00 amRNSAutolus announces partial exercise of ADS option
12th Dec 20223:05 pmRNSAutolus presents clinical data updates at ASH
9th Dec 20227:00 amRNSAutolus announces pricing of public offering
9th Dec 20227:00 amRNSFELIX trial of obe-cel meets its primary endpoint
6th Dec 202211:05 amRNSAchilles presents clinical data update
1st Dec 20227:19 amRNSAchilles to present clinical data update
1st Dec 20227:00 amRNSSyncona completes acquisition of AGTC
29th Nov 20227:14 amRNSNeogene to be acquired by AstraZeneca
29th Nov 20227:00 amRNSSyncona extends tender offer for AGTC
17th Nov 20227:00 amRNSHalf-year Report
15th Nov 202212:05 pmRNSFreeline reports Q3 2022 Financial Results
10th Nov 20222:05 pmRNSAnaveon presents updated data from ANV419
8th Nov 202212:05 pmRNSAchilles reports Q3 2022 Financial Results
3rd Nov 20221:39 pmRNSAutolus to present clinical data updates at ASH
3rd Nov 202211:05 amRNSAutolus Reports Q3 2022 Financial Results
27th Oct 20222:58 pmRNSNotice of Results
24th Oct 20227:00 amRNSSyncona to acquire AGTC
12th Sep 20227:00 amRNSAnaveon presents updated ANV419 data
17th Aug 202210:00 amRNSApplication for admission of shares to listing
16th Aug 20227:00 amRNS1st Quarter Results
9th Aug 202212:05 pmRNSAchilles reports Q2 2022 Financial Results
9th Aug 202212:05 pmRNSFreeline reports Q2 2022 Financial Results
4th Aug 202212:07 pmRNSAutolus Reports Q2 2022 Financial Results
3rd Aug 20221:15 pmRNSHolding(s) in Company
2nd Aug 202212:28 pmRNSResult of AGM
2nd Aug 20227:00 amRNSTotal Voting Rights
15th Jul 20227:00 amRNSIssue of shares pursuant to incentive scheme
11th Jul 20227:00 amRNSFreeline presents data in haemophilia B
7th Jul 20229:41 amRNSHolding(s) in Company
30th Jun 20229:00 amRNSPublication of 2022 Annual Report & Notice of AGM
22nd Jun 20225:21 pmRNSDirector Declaration
16th Jun 20227:00 amRNSFinal Results
10th Jun 20228:05 amRNSAutolus presents clinical data updates at EHA
8th Jun 20222:33 pmRNSHolding(s) in Company
19th May 20227:00 amRNSNotice of Results
18th May 202211:05 amRNSSyncona invests in $56 million SwanBio Series B

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.